.jpg)
Abstract
Background
MK-5475 is an investigational inhaled soluble guanylate cyclase stimulator hypothesised to avoid most side-effects of systemic vasodilation.
Methods
The phase 2 INSIGNIA-PAH (NCT04732221) trial randomised adults with pulmonary arterial hypertension (PAH) on stable background therapy 1:1:1:1 to once-daily dosing with placebo, MK-5475 32?µg, 100?µg or 380?µg via dry powder inhalation for 12?weeks.
Objectives
The objectives were to evaluate pulmonary vascular resistance (PVR; primary), 6-min walk distance (6MWD; secondary), additional selected haemodynamic parameters, and safety and tolerability in participants with PAH.
Results
168 participants were randomised to placebo (n=41), MK-5475 32?µg (n=42), 100?µg (n=44), and 380?µg (n=41). Median age was 51?years. Most participants were female (73.8%), diagnosed with idiopathic PAH (63.7%), receiving concomitant phosphodiesterase type 5 inhibitors (PDE5i; 93.5%), and treated with double or triple combination therapy (85.1%). At week 12, the placebo-corrected changes in PVR by least-squares means were ?9.2% (95% CI ?21.3%, 2.9%; p=0.068) with 32?µg, ?22.0% (95% CI ?33.7%, ?10.3%; p<0.001) with 100?µg, and ?19.9% (95% CI ?33.4%, ?6.4%; p=0.002) with 380?µg MK-5475. No treatment differences versus placebo were observed in 6MWD. Treatment-related adverse events and serious adverse events were similar across treatment groups. Three participants died: two on placebo and one on MK-5475 100?µg. One participant had symptomatic hypotension and one had haemoptysis (both on MK-5475 100?µg).
Conclusions
In participants with PAH on stable background therapy, including PDE5i, inhaled MK-5475 reduced PVR and was well tolerated, without evidence of systemic side-effects such as hypotension, suggesting a pulmonary selective pharmacodynamic effect.
